The acute renal failure (ARF) is the abrupt loss of the kidney functions, which lead to retention of bodily waste products, electrolyte disturbances, and volume status changes, relatively quickly. The smaller changes in kidney sometimes result in significant clinical consequences and increased morbidity and mortality. The causes of ARF have been primarily divided into three groups, namely, pre-renal, intrinsic, and post-renal.
In most of the renal failure cases, the kidney diseases do not show any early stage symptoms and, at times, remains undetected until it is advanced. People who are hospitalized with the highest risk in hospital intensive care units are at very high risk for acute kidney failure. Moreover, as per the National Kidney Foundation, the United States, about 10% of the population worldwide are affected by chronic kidney diseases. The experimental therapies for the management of renal failure targeted by the companies include growth factors, vasoactive peptides, adhesion molecules, endothelin inhibitors, and bioartificial kidneys.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world are provided, with data obtained from multiple sources. The report also includes a list of key sponsors, having pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on the data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation, by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation, by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence